| Mar-2025 | Dec-2024 | Sep-2024 | Jun-2024 | Mar-2024 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 0% | 0% | 0% | 0% | 0% |
Indian | 72.47% | 72.48% | 72.86% | 73.46% | 73.58% |
Total Promoter | - | - | - | - | - |
Institutions | 2.65% | 1.54% | 1.53% | 1.33% | 1.1% |
Non-Institutions | 24.86% | 25.96% | 25.59% | 25.2% | 25.3% |
Total Non-Promoter | 27.52% | 27.51% | 27.13% | 26.53% | 26.41% |
Custodian | 0% | 0% | 0% | 0% | 0% |
Total | 100% | 100% | 100% | 100% | 100% |
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
